Tara L. Lin
Expertise in
14
conditions

Dr. Tara L. Lin

Oncology
4350 Shawnee Mission Parkway, 
Fairway, KS 
Accepting New Patients
Offers Telehealth
24 Years of Experience
Expertise in
14
conditions
4350 Shawnee Mission Parkway, 
Fairway, KS 

Overview

Tara Lin is an Oncologist practicing medicine in Fairway, Kansas. She has been practicing medicine for over 24 years.

Dr. Lin is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Colonoscopy.

Dr. Lin is board certified in American Board Of Internal Medicine, Medical Oncology - 2005. She is actively involved in clinical research, co-authoring 109 peer reviewed articles and participating in 13 clinical trials. Dr. Lin is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in LA

Board Certifications

American Board Of Internal Medicine, Medical Oncology - 2005

Fellowships

David Geffen School of Medicine at UCLA, Stem Cell Research, 2008
Johns Hopkins University, Medical Oncology, 2006

Hospital Affiliations

University Of Kansas Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Clinical Research Center
4350 Shawnee Mission Parkway, Fairway, KS 66205
Other Locations
The University of Kansas Hospital
4000 Cambridge Street, Kansas City, KS 66160

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Other, Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes
A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes
Enrollment Status: Terminated
Publish Date: July 15, 2024
Intervention Type: Drug
Study Drugs: ONO-7475, Venetoclax
Study Phase: Phase 1/Phase 2
A Phase I-II Study of Triciribine Phosphate Monohydrate (PTX-200) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
A Phase I-II Study of Triciribine Phosphate Monohydrate (PTX-200) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Drug
Study Drugs: PTX-200, Cytarabine
Study Phase: Phase 1/Phase 2
A Phase 1B/2A, Open-label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Fosciclopirox Alone and In Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
A Phase 1B/2A, Open-label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Fosciclopirox Alone and In Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: February 12, 2024
Intervention Type: Drug
Study Drugs: Fosciclopirox, Cytarabine
Study Phase: Phase 1/Phase 2
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Enrollment Status: Terminated
Publish Date: November 15, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High Risk Myelodysplastic Syndrome
A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High Risk Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: August 31, 2023
Intervention Type: Drug
Study Drug: CB-5339
Study Phase: Phase 1
A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Study of Pyrimethamine, a STAT3 Inhibitor, for the Treatment of Intermediate/ High-risk Myelodysplastic Syndromes (MDS) That Has Relapsed or is Refractory to Azanucleosides
A Phase 1 Study of Pyrimethamine, a STAT3 Inhibitor, for the Treatment of Intermediate/ High-risk Myelodysplastic Syndromes (MDS) That Has Relapsed or is Refractory to Azanucleosides
Enrollment Status: Withdrawn
Publish Date: September 22, 2021
Intervention Type: Drug
Study Drug: Pyrimethamine
Study Phase: Phase 1
An Exploratory Trial to Estimate the Proportion of Patients With Tumor Cell Contaminated, Flow Positive Leukapheresis Products Collected With and Without Bortezomib as In-vivo Purging Prior to Autologous Stem Cell Harvest for Multiple Myeloma
An Exploratory Trial to Estimate the Proportion of Patients With Tumor Cell Contaminated, Flow Positive Leukapheresis Products Collected With and Without Bortezomib as In-vivo Purging Prior to Autologous Stem Cell Harvest for Multiple Myeloma
Enrollment Status: Completed
Publish Date: June 18, 2021
Intervention Type: Drug
Study Drugs: Bortezomib, Granulocyte Colony-Stimulating Factor (G-CSF), Mozobil
Study Phase: Phase 2
View 9 Less Clinical Trials

109 Total Publications

FLAG-Ida-venetoclax in acute myeloid leukemia: real-world efficacy and the impact of venetoclax duration on outcomes.
FLAG-Ida-venetoclax in acute myeloid leukemia: real-world efficacy and the impact of venetoclax duration on outcomes.
Journal: Leukemia & lymphoma
Published: July 15, 2026
Similar Doctors
Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

Medical Pavilion

2000 Olathe Boulevard, 
Kansas City, KS 
 (2.4 miles away)
913-588-1227
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Holzbeierlein is an Oncologist practicing medicine in Kansas City, Kansas. Dr. Holzbeierlein is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery. Dr. Holzbeierlein is board certified in American Board Of Urology, Urology - 2004. Dr. Holzbeierlein is currently accepting new patients.

Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Saint Luke's Cancer Specialists-Plaza

4401 Wornall Rd, 
Kansas City, MO 
 (2.9 miles away)
816-932-3300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Samuel Goldlust is an Oncologist practicing medicine in Kansas City, Missouri. Dr. Goldlust is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor. Dr. Goldlust is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

The University Of Kansas Hospital

4000 Cambridge Street, 
Kansas City, KS 
 (2.5 miles away)
913-588-1227
Languages Spoken:
English, Korean
See accepted insurances
Accepting New Patients
Offers Telehealth

Eugene Lee is an Oncologist practicing medicine in Kansas City, Kansas. Dr. Lee is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery. Dr. Lee is board certified in American Board Of Urology, Urology - 2015. Dr. Lee is currently accepting new patients.

Frequently Asked Questions about Dr. Tara L. Lin

How do I make an appointment with Dr. Tara L. Lin?

You can book an appointment with Dr. Tara L. Lin by calling their office at 913-588-1227. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Tara L. Lin a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Tara L. Lin is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Tara L. Lin specialize in?

While Dr. Tara L. Lin is a Oncology, they have specific expertise in Acute Myeloid Leukemia (AML), Leukemia, and Acute Myeloblastic Leukemia without Maturation. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Tara L. Lin participate in research or clinical trials?

Yes. Dr. Tara L. Lin has published 109 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Tara L. Lin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Tara L. Lin accept my insurance?

Dr. Tara L. Lin accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 913-588-1227 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lin's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile